Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Genmab is the lead sponsor of 31 current clinical trials in our USA, China, UK, Ireland and EU (CTIS) registers. 10 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Epcoritamab, Rina-S and Lenalidomide. The most-studied condition is Diffuse Large B-Cell Lymphoma.

Company profile on this site (news, sites, medicines, approvals): Genmab (DK) →

ClinicalTrials.gov trials by status

Recruiting1038%
Active, closed1662%

Trials by phase

Phase 31350%
Phase 1/2623%
Phase 2415%
Phase 1312%

Clinical trials sponsored by Genmab

26 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) NCT07702032 · Left-sided Colorectal Cancer Drugs: Cetuximab, Folfiri, MFOLFOX6	Phase 3	Recruiting	2026-08	USA
A Study of GEN1106 in Participants With Solid Tumors NCT07416123 · Solid Tumors, Urothelial Carcinoma	Phase 1	Recruiting	2026-04	USA
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer NCT07288177 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC) Drug: Rina-S	Phase 2	Recruiting	2026-01	USA, China
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers NCT07539311 · ClinicalTrials.gov ↗ · Gastrointestinal Cancers Drug: Rina-S	Phase 2	Recruiting	2026-05	USA
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366 · ClinicalTrials.gov ↗ · High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma Drugs: Bevacizumab, Carboplatin, Pembrolizumab	Phase 1/2	Recruiting	2022-12	USA, China
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy NCT07225270 · ClinicalTrials.gov ↗ · Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC Drugs: Bevacizumab, Rina-S	Phase 3	Recruiting	2026-04	USA
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer NCT07166094 · ClinicalTrials.gov ↗ · Endometrial Cancer, Recurrent or Progressive Endometrial Cancer Drug: Rina-S	Phase 3	Recruiting	2025-11	USA
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer NCT07564141 · ClinicalTrials.gov ↗ · Platinum-Sensitive Ovarian Cancer, Ovarian Cancer Drugs: Bevacizumab, Carboplatin, Gemcitabine	Phase 3	Recruiting	2026-08	USA
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors NCT07387068 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2026-04	USA
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China NCT07604766 · ClinicalTrials.gov ↗ · Platinum-resistant Ovarian Cancer Drugs: Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin	Phase 3	Recruiting	2026-06	China
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599 · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) Drugs: Carboplatin, Cisplatin, Gemcitabine	Phase 1/2	Active, closed	2019-09	UK, USA, China
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) NCT06635824 · PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC Drugs: Docetaxel, Pembrolizumab	Phase 3	Active, closed	2024-11	Ireland, UK, USA
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome NCT04623541 · Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome Drugs: Epcoritamab, Lenalidomide, Pirtobrutinib	Phase 1/2	Active, closed	2020-11	USA
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) NCT05578976 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma Drugs: Cyclophosphamide, Doxorubicin, Epcoritamab	Phase 3	Active, closed	2023-02	UK, USA, China
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) NCT04628494 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma Drug: Epcoritamab	Phase 3	Active, closed	2021-01	UK, USA
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma NCT05201248 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma Drugs: Cyclophosphamide, Doxorubicin, Epcoritamab	Phase 1/2	Active, closed	2022-03	China
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma NCT06191744 · ClinicalTrials.gov ↗ · Follicular Lymphoma (FL) Drugs: Bendamustine, Cyclophosphamide, Doxorubicin	Phase 3	Active, closed	2024-02	UK, USA, China
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma NCT03625037 · ClinicalTrials.gov ↗ · DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) Drug: Epcoritamab	Phase 1/2	Active, closed	2018-06	UK, USA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma NCT05409066 · ClinicalTrials.gov ↗ · Follicular Lymphoma (FL) Drugs: Epcoritamab, Lenalidomide, Rituximab	Phase 3	Active, closed	2022-09	UK, USA, China
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT06508658 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma Drugs: Epcoritamab, Gemcitabine, Lenalidomide	Phase 3	Active, closed	2024-08	UK, USA, China
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) NCT04663347 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma, Follicular Lymphoma Drugs: Epcoritamab, Gemcitabine and oxaliplatin, GemOx	Phase 1/2	Active, closed	2020-11	UK, USA
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer NCT06619236 · ClinicalTrials.gov ↗ · Platinum-resistant Ovarian Cancer Drugs: Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin	Phase 3	Active, closed	2025-02	USA, China
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma NCT05283720 · ClinicalTrials.gov ↗ · Non-Hodgkin Lymphoma Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Epcoritamab	Phase 2	Active, closed	2022-06	USA, China
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab NCT05206357 · ClinicalTrials.gov ↗ · Non-hodgkin Lymphoma Drug: Epcoritamab	Phase 1	Active, closed	2022-10	USA
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma NCT05451810 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma Drug: Epcoritamab	Phase 2	Active, closed	2022-08	USA
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China NCT07226752 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma Drug: Epcoritamab	Phase 3	Active, closed	2022-10	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Genmab in the EU trials register (CTIS)

5 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System with Genmab as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer 2025-524202-15-00 · Neoplasms Drugs: Bevacizumab, Carboplatin, Doxorubicin	Phase 3	Authorised	Ireland + 11 more
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers 2025-524130-26-00 · Neoplasms Drug: Pegfilgrastim	Phase 2	Authorised	Italy, Belgium, France + 4 more
A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC) 2025-522167-15-00 · CTIS ↗ · Neoplasms Drug: Bevacizumab	Phase 3	Ongoing	Finland, Belgium, Hungary + 9 more
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer 2025-522107-18-00 · CTIS ↗ · Neoplasms Drug: Pegfilgrastim	Phase 2	Ongoing	Germany, Hungary, Netherlands + 5 more
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator’s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy 2024-519818-31-01 · CTIS ↗ · Neoplasms Drugs: Doxorubicin, Paclitaxel	Phase 3	Ongoing	Poland, Denmark, Finland + 8 more

Drugs in Genmab trials

37 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Genmab trials

38 conditions

Diffuse Large B-Cell Lymphoma5 Follicular Lymphoma (FL)2 Ovarian Cancer2 Platinum-resistant Ovarian Cancer2PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC1Malignant Solid Tumor1Non-Small Cell Lung Cancer (NSCLC)1 Colorectal Cancer (CRC)1 Melanoma1 Diffuse Large B-cell Lymphoma1 DLBCL1High-grade B-cell Lymphoma (HGBCL)1Primary Mediastinal Large B-cell Lymphoma (PMBCL)1FL1Follicular Lymphoma1Relapsed/Refractory Chronic Lymphocytic Leukemia1Small Lymphocytic Lymphoma1Richter's Syndrome1Treatment-naïve High Risk Chronic Lymphocytic Leukemia1Left-sided Colorectal Cancer1Solid Tumors1 Urothelial Carcinoma1 Non-small Cell Lung Cancer (NSCLC)1 Non-Hodgkin Lymphoma1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	23	9
Clinical trials in China	12	3
Clinical trials in UK	9	0
Clinical trials in Ireland	1	0
EU register (CTIS)	5	—

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Diffuse Large B-Cell Lymphoma

Sponsor	Trials
First Affiliated Hospital of Ningbo University	2
Ting YANG	2

Sponsors with the most current trials registered for this condition.

Questions about Genmab trials

How many clinical trials does Genmab sponsor?

Genmab is the lead sponsor of 26 current trials on ClinicalTrials.gov in our USA, China, UK and Ireland registers, and 5 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Genmab trials recruiting?

Yes. 10 of its 26 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Genmab testing?

Its current trials name 37 drugs and biologicals as interventions. The most frequent are Epcoritamab (13), Rina-S (8), Lenalidomide (7), Paclitaxel (6) and Rituximab (6). The number in brackets is how many of its trials name each drug.

Does Genmab have clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Genmab clinical trials